Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ophthalmology/Conjunctivitis

Conjunctivitis

6

Pipeline Programs↗

8

Active Trials↗

28

Companies Involved↗

Conjunctivitis is an early-stage landscape with 6 programs across 28 companies. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

25/100

Mech. Concentration

100/100

Completion Rate

91/100

Attrition Rate

8/100

Pipeline

Programs by Phase

Preclinical3

Prednisolone Acetate

Novartis

Dexamethasone Sodium Phosphate

Quince Therapeutics S.p.A.

Sum-191

Senju USA, Inc.

Phase 1

No programs

Phase 2

No programs

Phase 33

Regn-2cat

Regeneron

Freneslerbart

Regeneron

Mevonlerbart

Regeneron

Approved

No programs

Analysis

Trial Status

191

clinical trials

Completed156 · 82%

Unknown status12 · 6%

Terminated10 · 5%

Recruiting6 · 3%

Withdrawn5 · 3%

Not yet recruiting1 · 1%

Other1 · 1%

Clinical Trials

Trial Activity

191 trials

Clinical Investigation of Daydrop® Triple Action for the Symptomatic Treatment of Allergic Conjunctivitis.

Recruiting·—·Preclinical·NCT07805759·49 enrolled

A Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Participants With Allergic Conjunctivitis Due to Cat Allergy

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT07675811·570 enrolled

A Phase I/II Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SUM-191 in Healthy Participants and in Participants With Bacterial Conjunctivitis

Recruiting·SSenju USA, Inc.·Preclinical·NCT07565103·426 enrolled

Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis

Recruiting·BBaxis Pharmaceuticals, Inc.·Phase 3·NCT06911424·400 enrolled

Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis

Recruiting·TTelios Pharma, Inc.·Phase 2·NCT07220408·60 enrolled

Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis

Recruiting·TTelios Pharma, Inc.·Phase 2·NCT06686472·66 enrolled

Patient Identification and Characterization (PIC) Study: A Prospective, Multicenter, Non-Interventional Study to Identify and Characterize Participants With Allergic Conjunctivitis With or Without Allergic Rhinitis Due to Cat and/or Birch Allergy

Not yet recruiting· Regeneron logo

Regeneron·N/A·NCT07710846·1,500 enrolled

Allogenic Plasma Aliquots in the Treatment of Ligneous Conjunctivitis

Enrolling by invitation·—·Phase 3·NCT04275232·1 enrolled

2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma

Completed·AAllergopharma GmbH & Co. KG·Phase 3·NCT01353755·195 enrolled

A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis

Completed·CCytos Biotechnology AG·Phase 2·NCT00574704·40 enrolled

Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis

Completed·—·Phase 3·NCT00409409·278 enrolled

Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02478398·1,025 enrolled

Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis

Completed·AAbbott·Phase 3·NCT02245360·107 enrolled

Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis

Completed· Sun Pharmaceutical Industries Limited logo

Sun Pharmaceutical Industries Limited·Phase 3·NCT00578955·417 enrolled

Safety of ToleroMune Ragweed to Treat Ragweed Allergy in Ragweed Allergic Subjects With Rhinoconjunctivitis

Completed·CCircassia Limited·Phase 2·NCT00878774·50 enrolled

Page 1 of 13

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)